Clinical Trial

Magnesium Sulfate as an Adjuvant to Lidocaine in MPDS Trigger Point Injections Assessed by VAS and sEMG.

Recruiting
View on ClinicalTrials.gov →
Summary
Two groups of patients diagnosed with Myofascial Pain Dysfunction Syndrome (MPDS) will be included in this study. One group will receive trigger point injections of lidocaine alone. The other group will receive trigger point injections of lidocaine combined with magnesium sulfate. The study aims to compare the effectiveness of both treatments in reducing pain and improving muscle function. Patients will be assessed using a pain scale (VAS) and surface electromyography (sEMG) to measure muscle activity.
Trial Details
NCT Number NCT07390851
Lead Sponsor Cairo University
Conditions Myofascial Pain Dysfunction Syndrome
Enrollment 28 participants
Start Date 2025-11-26
Primary Completion 2026-11-26 (estimated)
Study Completion 2026-11-26 (estimated)
Updated on ClinicalTrials.gov 2026-02-05